AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board

~Evaluation of Strategic Alternatives Ongoing~

LEXINGTON, Mass.–(BUSINESS WIRE)–Feb. 7, 2012–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the
appointment of Rajiv De Silva and Gino Santini to its board of
directors, effective immediately. Mr. De Silva is currently president of
Valeant Pharmaceuticals International, Inc. and chief operating officer
of its Specialty Pharmaceuticals business. Mr. Santini retired in 2010
from a 27-year career at Eli Lilly and Company, where he held a variety
of commercial and operational roles, serving most recently as senior
vice president, corporate strategy and business development. The
appointment of these two independent directors brings the AMAG Board to
seven members.

“As we continue to evaluate strategic alternatives for AMAG, the
perspective that Rajiv and Gino bring to the table will be invaluable to
AMAG and our board,” said Michael Narachi, chairman of AMAG’s board of
directors. “Rajiv’s operations experience at Valeant and Novartis,
coupled with Gino’s long history as a successful commercial leader and
experience defining and executing corporate strategy at Lilly will
support the key decisions facing the board in the coming months. Their
expertise will be valuable assets to the board as we explore a sale of
the company and simultaneously establish a solid foundation from which
to drive growth and profitability if AMAG remains an independent
company. ”

Mr. De Silva, age 45, joined Valeant in January 2009. He was named
Valeant’s president in October 2010 and is responsible for all specialty
pharmaceutical operations, including sales and marketing, research and
development, manufacturing and business development. From 2003 to 2009,
Mr. De Silva held various leadership positions of increasing
responsibility at Novartis AG, most recently as president, Novartis
Vaccines USA
and head, vaccines of the Americas. Prior to his time at
Novartis, Mr. De Silva was a partner at McKinsey & Company, a management
consulting firm, where he focused his consulting practice on the
pharmaceutical industry. Mr. De Silva holds a Bachelor of Science in
Engineering from Princeton University, a Master of Science from Stanford
, and a Master of Business Administration from the Wharton
at the University of Pennsylvania.

Mr. Santini, age 55, had a distinguished career with Eli Lilly that
spanned nearly three decades. During his tenure at Lilly, Mr. Santini
held various leadership positions of increasing responsibility,
including manager of various international regions, president of the
women’s health franchise and president of U.S. operations. Mr. Santini
capped his career at Lilly as a member of the company’s executive
committee and as the senior vice president of corporate strategy and
business development. Mr. Santini, fluent in four languages, holds an
undergraduate degree in mechanical engineering from the University of
and a master’s in business administration from the University of

Mr. Narachi continued, “While we continue the strategic review process,
we are progressing our effort to identify and interview qualified
candidates for the position of chief executive officer of AMAG.”

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that
manufactures and markets Feraheme® in the United States. For additional
company information, please visit

About Feraheme

In the United States, Feraheme® (ferumoxytol) Injection for Intravenous
(IV) use is indicated for the treatment of iron deficiency anemia in
adult chronic kidney disease (CKD) patients. Feraheme received
marketing approval from the U.S. Food and Drug Administration on June
30, 2009
and was commercially launched by AMAG in the U.S. shortly
thereafter. For additional product information, please visit

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. Any statements contained herein which do
not describe historical facts, including but not limited to our
evaluation of strategic alternatives, including a potential sale of the
company; our efforts to establish a solid foundation from which to drive
growth and profitability if we remain independent; and Mr. De Silva’s
and Mr. Santini’s potential contributions to our Board of Directors; are
forward-looking statements which involve risks and uncertainties that
could cause actual results to differ materially from those discussed in
such forward-looking statements.

Such risks and uncertainties include: (1) uncertainties regarding our
ability to successfully compete in the intravenous iron replacement
market both in the U.S. and outside the U.S., (2) uncertainties
regarding our ability to successfully and timely complete our clinical
development programs and obtain regulatory approval for Feraheme in new
indications and in territories outside of the U.S., including the
European Union, (3) the fact that significant safety or drug interaction
problems could arise with respect to Feraheme, (4) uncertainties
regarding our ability to manufacture Feraheme, (5) uncertainties
relating to our patents and proprietary rights, (6) uncertainties
regarding the outcome of our evaluation of strategic alternatives,
including the risk that the process will not result in a transaction,
and (7) other risks identified in our Securities and Exchange Commission
filings, including our Annual Report on Form 10-K for the year ended
December 31, 2010 and our Quarterly Report on Form 10-Q for the three
and nine months ended September 30, 2011. We caution you not to place
undue reliance on any forward-looking statements, which speak only as of
the date they are made.

We disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be based,
or that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303